Bepranemab

CAS No. 2244960-75-4

Bepranemab( —— )

Catalog No. M36774 CAS No. 2244960-75-4

Bepranemab (UCB 0107), a humanized full-length IgG4 monoclonal antibody, targets the central tau epitope (amino acids 235-250) and is utilized in Alzheimer’s disease (AD) research .

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Bepranemab
  • Note
    Research use only, not for human use.
  • Brief Description
    Bepranemab (UCB 0107), a humanized full-length IgG4 monoclonal antibody, targets the central tau epitope (amino acids 235-250) and is utilized in Alzheimer’s disease (AD) research .
  • Description
    Bepranemab (UCB 0107) is a humanized, full-length IgG4 monoclonal antibody that binds to a central tau epitope (amino acids 235-250). Bepranemab can be used for Alzheimer’s disease (AD) research.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2244960-75-4
  • Formula Weight
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Matthew E Barton, et al. Design of a patient- and investigator-blind, randomized, placebo-controlled study to evaluate efficacy, safety, and tolerability of bepranemab, UCB0107, in prodromal to mild Alzheimer’s disease: The TOGETHER Study, AH0003. Alzheimer's & Dementia. 31 December 2021.
molnova catalog
related products
  • Caerulein, desulfate...

    Caerulein, desulfated is the desulfurated form of Caerulein. Caerulein is a deceptide with the same five carboxy-terminal amino acids as gastrin and cholecystatin (CCK).

  • ADWX 1

    Potent and selective KV1.3 channel blocker (IC50 values are 0.0019 and 0.65 nM for KV1.3 and KV1.1, respectively). Inhibits CD4+ CCR7- T cell activation. Ameliorates rat experimental autoimmune encephalomyelitis, in a model for multiple sclerosis.

  • JNJ-1661010

    JNJ-1661010 is an effective and specific FAAH inhibitor (IC50: 10/ 12 nM for rat/human), shows >100-fold selectivity for FAAH-1 than FAAH-2.